2020•British Journal of HaematologyRequires access

Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy

Wei Liu, Wenyang Huang, Min Wang, Rui Lv, Jian Li, Ying Wang, Shuhui Deng, Shuhua Yi, Hong Shu Liu, Qing Rao, Yingxi Xu, Lulu Lv, Lugui Qiu, Dehui Zou, Jianxiang Wang

Open publisher page 24 citations

Abstract

The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Medicine, HBsAg, Hepatitis B virus, Hepatitis B, Rituximab, Lymphoma, Immunology, Internal medicine